Revolution Medicines (RVMD) vs Bio-Techne (TECH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Revolution Medicines (RVMD) has outperformed Bio-Techne (TECH) over the past year, gaining 331.3% versus a gain of 22.5%. Over five years, RVMD leads with a +645.3% price change compared with -41.7% for TECH. Revolution Medicines is the larger company by market cap ($43.05 billion vs $11.37 billion), about 3.8 times the size.
Bio-Techne pays a dividend yielding 0.44%, while Revolution Medicines does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RVMD | TECH |
|---|---|---|
| Share price | $200.87 | $72.53 |
| Market cap | $43.05B | $11.37B |
| 1-day change | +0.50% | +0.14% |
| YTD return | +152.19% | +23.33% |
| 1-year return | +331.33% | +22.54% |
| 5-year return | +645.34% | -41.75% |
| P/E ratio (TTM) | — | 62.53 |
| Forward P/E | — | 31.36 |
| EPS (TTM) | $-8.53 | $1.16 |
| Dividend yield | 0.00% | 0.44% |
| Annual dividend | $0.00 | $0.32 |
| Revenue (latest FY) | $0 | $1.22B |
| Revenue growth (YoY) | — | -0.38% |
| Net income (latest FY) | $-1.13B | $181.86M |
| Gross margin | — | 65.77% |
| Operating margin | — | 20.73% |
| Net margin | — | 14.97% |
| 52-week high | $224.31 | $72.69 |
| 52-week low | $47.28 | $43.20 |
| Distance from 52-week high | -10.45% | -0.22% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +28.86% | -2.80% |
| Average volume | 1.88M | 3.08M |
| Shares outstanding | 214.34M | 156.82M |
| Employees | 883 | 3,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Revolution Medicines is about 3.8 times larger than Bio-Techne by market value ($43.05B vs $11.37B).
- RVMD has outperformed TECH by 308.8 percentage points over the past year.
About Revolution Medicines
RVMD stock →Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees
About Bio-Techne
TECH stock →Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 3,000 employees
RVMD vs TECH FAQ
Which is bigger, Revolution Medicines or Bio-Techne?
Revolution Medicines (RVMD) is larger, with a market capitalization of $43.05B compared with $11.37B for Bio-Techne (TECH).
Which stock has performed better over the past year, RVMD or TECH?
RVMD returned +331.33% over the past 12 months, compared with +22.54% for TECH (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Revolution Medicines or Bio-Techne?
Bio-Techne pays a dividend yielding 0.44%, while Revolution Medicines does not currently pay a regular dividend.
Are Revolution Medicines and Bio-Techne in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.